These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 24595274)

  • 21. A novel 2.5D culture platform to investigate the role of stiffness gradients on adhesion-independent cell migration.
    Pebworth MP; Cismas SA; Asuri P
    PLoS One; 2014; 9(10):e110453. PubMed ID: 25310593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using the neurofibromatosis tumor predisposition syndromes to understand normal nervous system development.
    Garcia C; Gutmann DH
    Scientifica (Cairo); 2014; 2014():915725. PubMed ID: 25243094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small molecule integrin antagonists in cancer therapy.
    Paolillo M; Russo MA; Serra M; Colombo L; Schinelli S
    Mini Rev Med Chem; 2009 Oct; 9(12):1439-46. PubMed ID: 19929817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathological and molecular biological approaches to early mesothelioma.
    Tsujimura T; Torii I; Sato A; Song M; Fukuoka K; Hasegawa S; Nakano T
    Int J Clin Oncol; 2012 Feb; 17(1):40-7. PubMed ID: 22237727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.
    Cheng NC; van Zandwijk N; Reid G
    PLoS One; 2014; 9(3):e90374. PubMed ID: 24595274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
    Maurer GD; Tritschler I; Adams B; Tabatabai G; Wick W; Stupp R; Weller M
    Neuro Oncol; 2009 Dec; 11(6):747-56. PubMed ID: 19221171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting αvβ3 and αvβ5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model.
    Gvozdenovic A; Boro A; Meier D; Bode-Lesniewska B; Born W; Muff R; Fuchs B
    Oncotarget; 2016 Aug; 7(34):55141-55154. PubMed ID: 27409827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.
    Mikkelsen T; Brodie C; Finniss S; Berens ME; Rennert JL; Nelson K; Lemke N; Brown SL; Hahn D; Neuteboom B; Goodman SL
    Int J Cancer; 2009 Jun; 124(11):2719-27. PubMed ID: 19199360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells.
    Alghisi GC; Ponsonnet L; Rüegg C
    PLoS One; 2009; 4(2):e4449. PubMed ID: 19212436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction.
    Leblond P; Dewitte A; Le Tinier F; Bal-Mahieu C; Baroncini M; Sarrazin T; Lartigau E; Lansiaux A; Meignan S
    Anticancer Drugs; 2013 Sep; 24(8):818-25. PubMed ID: 23728220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenotypes and karyotypes of human malignant mesothelioma cell lines.
    Relan V; Morrison L; Parsonson K; Clarke BE; Duhig EE; Windsor MN; Matar KS; Naidoo R; Passmore L; McCaul E; Courtney D; Yang IA; Fong KM; Bowman RV
    PLoS One; 2013; 8(3):e58132. PubMed ID: 23516439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination therapy of cilengitide with belotecan against experimental glioblastoma.
    Kim YH; Lee JK; Kim B; DeWitt JP; Lee JE; Han JH; Kim SK; Oh CW; Kim CY
    Int J Cancer; 2013 Aug; 133(3):749-56. PubMed ID: 23354807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Matched rabbit monoclonal antibodies against αv-series integrins reveal a novel αvβ3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors.
    Goodman SL; Grote HJ; Wilm C
    Biol Open; 2012 Apr; 1(4):329-40. PubMed ID: 23213423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies.
    Reardon DA; Cheresh D
    Genes Cancer; 2011 Dec; 2(12):1159-65. PubMed ID: 22866207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anoikis: an emerging hallmark in health and diseases.
    Taddei ML; Giannoni E; Fiaschi T; Chiarugi P
    J Pathol; 2012 Jan; 226(2):380-93. PubMed ID: 21953325
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.